Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.
Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the safety and tolerability benefitsof darolutamide (Nubeqa) in men with nonmetastatic castration resistant prostate cancer (CRPC).
Data from the prospective phase 3 SPARTAN, PROSPER, and ARAMIS trials led to the approvals of apalutamide (Erleada), enzalutamide (Xtandi), and darolutamide (Nubeqa) in nonmetastatic CRPC, respectively, says Shore.
At the 2020 ASCO Virtual Scientific Program, a matching-adjusted indirect comparisons (MAICs) study was presented regarding key data obtained from the 3 studies, says Shore. This methodology enabled investigators to do a comparative analysis of the safety data and adverse effect (AE) profile of these agents, Shore explains.
The analysis showed that darolutamide may have a tolerability and safety advantage compared with apalutamide and enzalutamide, Shore concludes.